PharmaMar will present new data for Zepzelca® (lurbinectedin) at rescheduled IASLC 2020

One oral presentation and three posters will be presented on lurbinectedin during the Congress. Results of the phase I-II study of lurbinectedin in combination with irinotecan in relapsed Small Cell Lung Cancer (SCLC) will be presented in an oral session. PharmaMar (MSE:PHM), along with Jazz Pharmaceuticals plc (Nasdaq: JAZZ), has announced today that the International Association for the Study of Lung Cancer (IASLC) has released the abstracts to be presented during the IASLC 2020 World Conference on Lung Cancer, which will be held virtually from January 28th to 31st. One oral presentation and three posters will be presented on Zepzelca® (lurbinectedin) during the congress. In the oral presentation, new data on the lurbinectedin combination with irinotecan in relapsed Small Cell Lung Cancer (SCLC) will be presented, under the abstract “Lurbinectedin with irinotecan in relapsed small cell lung cancer. Results from the expansion stage of a phase I-II trial“. This combination of lurbinectedin and irinotecan demonstrated efficacy in SCLC after failure of first-line therapy, including “remarkable activity in patients with resistant disease (CTFI <90 days) and in the 3rd line setting”. Moreover, toxicity was transient and manageable, and consisted mainly of hematological abnormalities, fatigue and diarrhea. The updated results of this cohort will be presented at the conference. In addition, the Company will present the poster “Semi-mechanistic models of the Time Course of Neutrophils and Platelets in Cancer patients treated with lurbinectedin“, which shows that lurbinectedin dosed at 3.2 mg/m² administered every three weeks can be safely administered without primary prophylaxis. These data have demonstrated that in cancer patients receiving lurbinectedin, neutropenia and thrombocytopenia observed were non-cumulative, reversible, short lasting and clinically manageable. In the poster entitled “Exposure-Response Analyses and Clinical Utility Index to Justify the Dosage of Lurbinectedin in Small-cell Lung Cancer”, the Company will present new results on the recommended lurbinectedin dosing regimen of 3.2 mg/m² every three weeks, providing maximum benefit in SCLC patients with disease progression. Finally, a ‘trial in progress’ poster will also be presented with the design of a new phase I-II study for the combination of lurbinectedin with pembrolizumab: “Lurbinectedin in combination with Pembrolizumab for patients with relapsed Small Cell Lung Cancer. LUPER Clinical Trial“. The studies presented at the IASLC 2020 Congress are available at: https://library.iaslc.org/conference-program?product_id=20 Outstanding studies in IASLC 2020 Congress Zepzelca® (lurbinectedin) Lurbinectedin with irinotecan in relapsed small cell lung cancer. Results from the expansion stage of a phase I-II trial. Oral Presentation. 28.01.2021. 15:30-16:30 (GMT +8). Presenting author: Santiago Ponce. Authors: Gregory Coté, Alajandro Falcón, Elizabeth Jimenez-Aguilar, Jessica J. Lin, Inmaculada Sánchez Simón, Maria José Flor, Rafael Nuñez, Ana María Jimenez, Eva Jimenez, Sonia Extremera, Carmen Kahatt, Ali Zeaiter, Luis G. Paz-Ares Semi-mechanistic Models of the Time Course of Neutrophils and Platelets in Cancer Patients Treated With Lurbinectedin Poster. 28.01.2021. Presenting Author: Salvador Fudio. Authors: Carlos Fernandez Teruel, Rubin Lubomirov. Exposure-Response Analyses and Clinical Utility Index to Justify the Dosage of Lurbinectedin in Small-cell Lung Cancer Poster. 28.01.2021. Presenting Author: Salvador Fudio. Authors: Carlos Fernandez Teruel, Rubin Lubomirov. Lurbinectedin in Combination with Pembrolizumab for Patients with Relapsed Small Cell Lung Cancer. LUPER Clinical Trial Poster. 28.01.2021. Authors: Maria José De Miguel Luken, Bernard Gaston Doger Speville Uribe, Alejandro Navarro, Roldán Cortés, Antonio Calles.

The release as fetched from its publisher. pharmamar.com ↗